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Abstract 
Background: We carried out a case–control study in patients with type 2 diabetes mellitus (T2DM) to evaluate the 
association between seven single nucleotide polymorphisms (SNPs) previously described to be linked to diabetic kid-
ney disease (DKD) in type 1 diabetes mellitus (T1DM). Additionally, we evaluated gene and protein expression related 
to the polymorphism associated with DKD.
Methods: The association study included 1098 T2DM patients (718 with DKD and 380 without DKD). Out of the 13 
polymorphisms associated with DKD in a previous study with T1DM, seven were chosen for evaluation in this sample: 
rs1888747, rs9521445, rs39075, rs451041, rs1041466, rs1411766 and rs6492208. The expression study included 91 
patients who underwent nephrectomy. Gene expression was assessed by RT-qPCR and protein expression in kidney 
samples was quantified by western blot and it localization by immunohistochemistry.
Results: The C/C genotype of rs1888747 SNP was associated with protection for DKD (OR = 0.6, 95 % CI 0.3–0.9; 
P = 0.022). None of the other SNPs were associated with DKD. rs1888747 is located near FRMD3 gene. Therefore, 
FRMD3 gene and protein expression were evaluated in human kidney tissue according to rs1888747 genotypes. Gene 
and protein expression were similar in subjects homozygous for the C allele and in those carrying the G allele.
Conclusions: Replication of the association between rs1888747 SNP and DKD in a different population suggests that 
this link is not the result of chance. rs1888747 SNP is located at the FRMD3 gene, which is expressed in human kidney. 
Therefore, this gene is a candidate gene for DKD. However, in this study, no rs1888747 genotype or specific allele 
effect on gene and/or protein expression of the FRMD3 gene was demonstrated.
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Background
Diabetic kidney disease (DKD) is currently one of the 
main causes of end-stage renal disease (ESRD) [1–5], 
with an estimated incidence of 26 % in patients starting 
dialysis [6]. In addition to ESRD, DKD also causes an 
important increase in cardiovascular-related morbidity 
and mortality [6, 7].
An increasing body of evidence supports a genetic basis 
for DKD [8, 9]. However, little is known about the mode 
of transmission, which is probably polygenic, or about 
the mechanisms of gene-environment interaction. Until 
this moment, genome wide-association study (GWAS) 
and candidate gene studies have produced heterogeneous 
results [8–13].
A GWAS of 360,000 single nucleotide polymorphisms 
(SNPs) has identified 13 SNPs associated with DKD 
in two independent populations of patients with type 
1 diabetes mellitus (T1DM) [14]. The strongest asso-
ciation was observed at the FRMD3 (4.1 protein ezrin, 




*Correspondence:  luishenriquecanani@gmail.com 
1 Endocrine Division, Hospital de Clínicas de Porto Alegre, Rua Ramiro 
Barcelos 2350, prédio 12, 4° andar, Porto Alegre, RS 90035-003, Brazil
Full list of author information is available at the end of the article
Page 2 of 10Buffon et al. Diabetol Metab Syndr  (2016) 8:3 
Moreover, other relevant association was observed at 
CARS (cysteinyl-tRNA synthetase) locus. Confirmation 
of implicated SNPs was obtained in participants of the 
Diabetes Control and Complications Trial (DCCT)/Epi-
demiology of Diabetes Interventions and Complications 
(EDIC) study [15–17].
Because patients with T1DM and type 2 diabetes melli-
tus (T2DM) might share common genes related to DKD, 
the present study was designed to (1) investigate whether 
the SNPs found to be associated with DKD in T1DM are 
also associated with DKD in T2DM; (2) evaluate the asso-
ciation of these SNPs in early (microalbuminuria) and 
advanced stages of DKD (macroalbuminuria or ESRD); 
and (3) evaluate gene and protein expression of the genes 
associated with DKD in human kidney biopsies.
Methods
Patients analyzed in the association study
A case–control study was conducted with 1098 white 
T2DM patients selected from a cross-sectional study 
performed in the state of Rio Grande do Sul, Brazil [11]. 
T2DM was defined according to World Health Organi-
zation criteria [18]: diagnosis of diabetes after the age of 
35 years, no use of insulin during the first year after diag-
nosis, and no episodes of diabetic ketoacidosis. Control 
T2DM patients were those with known diabetes dura-
tion of at least 5  years and normoalbuminuria (albumi-
nuria <30  mg/24  h, n  =  380). Cases were divided into 
two categories: early DKD (albuminuria 30–299 mg/24 h, 
n = 323) or advanced DKD (albuminuria ≥300 mg/24 h 
or ESRD, n  =  395). The protocol was approved by the 
ethics committee, and all patients gave their written 
informed consent.
All patients underwent an evaluation that included a 
standardized questionnaire and physical examination, 
as previously described [19]. Briefly, information was 
collected about age, age at T2DM diagnosis, drug treat-
ment and smoking. They were weighed bare feet, wear-
ing light outdoor clothes and their height was measured. 
Body mass index (BMI) was calculated as weight (kg)/
height2 (meters). For patients on dialysis, the mean of 
three weights measured after dialysis sessions were 
used. Hypertension was defined as blood pressure (BP) 
≥140/90 mmHg or use of any antihypertensive medica-
tion. BP was defined based on the mean of two measure-
ments in the sitting position using a standard mercury 
sphygmomanometer (phases I and V of Korotkoff). Dia-
betic retinopathy (DR) was assessed by fundus examina-
tion after mydriasis by an experienced ophthalmologist 
and graded as absent, non-proliferative or proliferative 
diabetic retinopathy.
Fasting blood samples were collected for laboratory 
and molecular analyses. Fasting plasma glucose was 
determined by a glucose oxidase method and HbA1c by 
an ion-exchange high performance liquid chromatogra-
phy procedure (Merck-Hitachi L-9100 Glycated Hemo-
globin Analyzer, Tokyo, Japan) with inter- and intra-assay 
coefficient of variation (CV) of 2.4 and 0.5 %, respectively 
(reference interval 4.1–6.0 %) [20]. Serum creatinine was 
determined by the Jaffé reaction [21]. Triglycerides and 
cholesterol levels were measured by enzymatic meth-
ods. LDL-cholesterol was calculated using the Friede-
wald equation. Urinary albumin excretion (UAE) was 
measured in 24 h-urine samples by immunoturbidimetry 
(Bayer, TarryTown, NY, USA), with intra- and interassay 
CV of 4.5 and 11 % respectively [22]. Use of angiotensin-
converting enzyme inhibitors or angiotensin receptor 
antagonists was interrupted at least 1 week before albu-
minuria measurement.
DNA isolation and genotyping
DNA was extracted from peripheral blood leukocytes 
by a standardized salting-out procedure. Seven out of 
13 SNPs initially associated with DKD in T1DM in the 
GoKinD Study [15] were chosen to be included in the 
present study (rs1888747, rs9521445, rs39075, rs451041, 
rs1411766, rs6492208, rs1041466). Not all 13 SNPs were 
genotyped because some of them were in linkage dis-
equilibrium (LD): rs1888747 and rs10868025 (r2 = 0.81), 
both located at chromosome 9q; rs39059 and rs39075 
(7p, r2  >  0.96); rs451041 and rs739401 (11p, r2  >  0.87), 
rs9521445 and 7989848 (13q, r2  >  0.87), rs1411766 and 
17412858 (13q, r2  =  1), and rs6492208 and rs2391777 
(13q, r2 = 1) [15]. In LD pairs, the SNP having the strong-
est association with DKD was chosen for analysis. LD 
data was obtained from the HapMap Project (http://
www.hapmap.org) for the Caucasian population. Poly-
morphism loci analyzed are shown in the supplementary 
material (Additional file 1: Table S1).
All polymorphisms were genotyped using primers 
and probes contained in the Human Custom TaqMan 
Genotyping Assay (40×) (Assays-By-Design Service, Life 
Technologies, Foster City, CA; USA). Primer and probe 
sequences used for genotyping these SNPs are described 
in Additional file 1: Table S2. Real-time (RT) PCR reac-
tions were conducted in 96-well plates, in 5  µl total 
reaction volume using 2  ng of genomic DNA, TaqMan 
Genotyping Master Mix (1×) (Life Technologies), and 
Custom TaqMan Genotyping Assay (1×). Plates were 
positioned in a RT PCR thermal cycler (7500 Fast Real 
PCR System; Life Technologies) and heated for 10  min 
at 95  °C, followed by 40–50 cycles at 95  °C for 15  s 
and 60–62  °C for 1  min. The percentage of duplicates 
included in genotyping was 10  %. Genotyping success 
was more than 95 %, with a calculated error rate based on 
PCR duplicates of <0.01 %.
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FRMD3 expression in kidney tissue samples
For gene expression analysis, kidney tissue samples 
were collected from 91 patients undergoing therapeutic 
nephrectomy over a period of 30 months at Hospital de 
Clínicas de Porto Alegre. A standard questionnaire was 
used to collect information regarding age, gender, pres-
ence of arterial hypertension, diabetes mellitus, and 
smoking habit. A peripheral blood sample was collected 
from each subject for DNA extraction and genotyping. 
Excised normal kidney tissue was divided into aliquots 
for mRNA expression analyses and evaluation of protein 
expression and localization by western blot (WB) and 
immunohistochemistry (IHC), respectively. From 91 kid-
ney samples analyzed for gene expression, only 48 kidney 
samples were utilized for protein expression analyzes, 
since 30 samples lacked enough material for proper pro-
tein extraction and the protein extraction was unsuccess-
ful in 13 samples due to technical difficulties. The study 
protocol was approved by the Hospital’s ethics commit-
tees, and all patients gave their written informed consent.
RNA isolation and quantification of FRMD3 gene 
expression by real‑time reverse transcription PCR
Kidney biopsies were homogenized in phenol/guanidine 
isothiocyanate (Invitrogen Life Technologies, Carlsbad, 
CA). RNA was extracted with chloroform and precipi-
tated with isopropanol by centrifugation (12,000×g) at 
4  °C. RNA pellet was washed twice with 75  % ethanol 
and resuspended in 10–50  μl of diethylpyrocarbonate 
treated water. Concentrations of isolated RNAs were 
assessed using NANODROP 2000 spectrophotometer 
(Thermo Scientific Inc., DE, USA). Only total RNA sam-
ples achieving adequate purity ratios (A260/A280 = 1.9–
2.1) were used for subsequent analyses [23]. In addition, 
RNA integrity and purity were also checked on agarose 
gel containing Gel Red Nucleic Acid Gel Stain (Biotium 
Inc, Hayward, CA). The mean (±  SD) concentration of 
isolated RNA was 2.68 ± 1.69 µg/250 mg kidney.
Real-time reverse transcription-PCR (RT-qPCR) was 
performed in two separate reactions: first, RNA was 
reverse transcribed into cDNA, and subsequently cDNA 
was amplified by RT-qPCR. Reverse transcription of 5 µg 
of RNA into cDNA was carried out using the Super Script 
Vilo Master Mix Kit (Synthesis System for RT-PCR; Invit-
rogen). RT-qPCR experiments were performed in a 7500 
Real Time PCR System (Life Technologies). Experiments 
were performed by real-time monitoring of the increase 
in fluorescence of SYBER Green dye [24]. Primers were 
designed using Primer Express 3.0 Software (Life Tech-
nologies) and are depicted in Additional file 1: Table S2.
PCR reactions were performed using 10  µl of SYBER 
Green (1×) (Life Technologies), 1  µl of specific prim-
ers, FRMD3 or cyclophilin A (Invitrogen), 7  µl of water 
and 1 μl of cDNA (0.2 μg/μl) in a total volume of 20 μl. 
Each sample was assayed in triplicate and a negative con-
trol was included in each experiment. The thermocycling 
conditions for these genes were as follows: an initial cycle 
of 95 °C for 10 min, followed by 50 cycles of 95 °C for 15 s 
and 60 °C for 1:30 min.
Quantification of FRMD3 cDNA was performed 
using the ∆∆Cq method [23, 25] and expressed relative 
to the reference gene (cyclophilin A) in 91 kidney tis-
sue samples: 76 carrying the G allele (GG or GC) of the 
rs1888747 SNP, and 15 with the CC genotype. Validation 
assays were done by separate amplification of the target 
(FRMD3) and reference (cyclophilin A) genes using serial 
dilutions of a cDNA sample. As a requirement of this 
method, both target and reference genes exhibited equal 
amplification efficiencies (E  =  95–105  %) in all experi-
ments. The ∆∆Cq method calculates changes in gene 
expression as relative fold differences (n-fold changes) 
between an experimental and an external calibrator sam-
ple [23]. RT-qPCR specificity was determined using melt-
ing curve analyses and all primers generated amplicons 
that produced a single sharp peak during the analyses 
[26].
Determination of FRMD3 protein distribution 
and concentration in kidney
FRMD3 protein distribution and concentrations were 
determined in only 48 kidney sections, due to insufficient 
material for protein extraction. Thirty-nine of these sec-
tions belonged to subjects carrying the rs1888747 SNP 
G allele (GG =  23 and CG =  16). FRMD3 protein dis-
tribution was evaluated by IHC of formalin-fixed, par-
affin-embedded kidney sections, while FRMD3 protein 
quantities were determined using WB. For IHC analyses, 
a goat rabbit anti-FRMD3 polyclonal antibody (Abcam, 
Cambridge, MA, USA) was used to detect FRMD3 pro-
tein distribution in human kidney tissue. IHC analyses 
were performed on 4  μm-thick kidney sections [27]. 
The routine IHC technique comprised: deparaffiniza-
tion and rehydration, antigenic recovery, inactivation 
of endogenous peroxidase and blocking of nonspecific 
reactions. Slides were incubated with primary antibody 
and then incubated again with a biotinylated second-
ary antibody, streptavidin horseradish peroxidase con-
jugate (LSA; Dako Cytomation Inc, Carpinteria, CA, 
USA), and diamino benzidine tetra hydrochloride (Kit 
DAB Dako Cytomation Inc). Images were visualized 
through a Zeiss microscope (model AXIOSKOP-40; Carl 
Zeiss, Oberkochen, Germany) and captured using the 
Cool Snap-Pro CS (Media Cybernetics, Rockville, USA) 
camera.
For WB analyses, proteins from human kidneys were 
extracted using RIPA buffer and quantified using a 
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colorimetric BCA™ Protein Assay Kit (Thermo Scien-
tific). Protein extracts (20  µg) were resolved on 10  % 
polyacrylamide gels, transferred to Immobilon®-PSQ 
membranes (Millipore, Billerica, MA, USA), and incu-
bated with monoclonal antibodies to FRMD3 (Bioss, 
Woburn, MA, USA) or β-Actin (Millipore) overnight. 
Secondary antibodies consisted of horseradish peroxi-
dase conjugated goat anti-rabbit antibodies (Millipore). 
Detection was performed using Immobilon Western 
Chemiluminescent HRP Substrate (Millipore), and 
images were acquired and quantified in an Image Quant 
LAS 500 (GE Healthcare, Pittsburgh, USA) digital imag-
ing system. Initially, the process was applied for FRMD3 
antibody. After stripping, the membrane was re-blotted 
with β-Actin antibody. Data are expressed as arbitrary 
units (AU). Three isoforms of FRMD3 protein (http://
www.uniprot.org/uniprot/A2A2Y4) were quantified sep-
arately (data not shown) and grouped by WB.
Statistical analyses
In the association study, we compared controls vs. cases 
(defined as any degree of DKD) and controls vs. differ-
ent DKD stages (microalbuminuria, macroalbuminu-
ria/ESRD). Data were analyzed assuming dominant, 
recessive and additive inheritance models to determine 
the best fit. Allele frequencies of all SNPs were deter-
mined by gene counting, and departures from Hardy-
Weinberg equilibrium (HWE) were verified using the 
Chi square (χ2) test. Allele and genotype frequencies 
were compared between groups using the χ2 test. Con-
tinuous data with normal distribution are presented as 
mean  ±  SD, while continuous variables with skewed 
distribution were log-transformed before analysis and 
are presented as medians (minimum–maximum val-
ues), with exception of FRMD3 protein concentration 
(WB) for which log-transformation did not normal-
ize the variable, thus we used the non-log variable and 
non-parametric tests. Categorical data are expressed 
as number of cases and percent of individuals affected. 
One-way analysis of variance (ANOVA), χ2 or Student’s 
t test were used to compare the groups in terms of clin-
ical and laboratory characteristics or FRMD3 gene/pro-
tein expression. The magnitude of the association was 
estimated using odds ratios (ORs) with 95 % confidence 
interval (95 % CI). Multiple logistic regression analysis 
was used to evaluate the independence of possible SNP 
associations with DKD, adjusting for covariables. Pear-
son’s correlation test was used to evaluate correlation 
between quantitative variables. Multiple linear regres-
sion analyses were performed with FRMD3 gene or 
protein expression as dependent variables and age and 
sex as independent variables. Results for which P < 0.05 
were considered statistically significant. All statistical 




We evaluated 1098 T2DM patients, of which 718 (65.4 %) 
had DKD (323 microalbuminuric and 395 macroalbumi-
nuric/ESRD subjects). Patients with DKD had higher BP, 
higher prevalence of DR, and a worse lipid profile com-
pared to the control group (Additional file  1: Table S3). 
Both groups had similar HbA1c levels.
Genotypes of the SNPs analyzed in the present study 
were in HWE (P > 0.05), with exception of the rs1411766 
and rs6492208 SNPs. Because no genotyping errors were 
detected, these SNPs were maintained in the study. Gen-
otype distributions are shown in Table 1. Of these seven 
SNPs, only rs1888747 was significantly associated with 
DKD (CC/CG/GG = cases vs. controls = 6.8/41.5/51.7 % 
vs 10.8/40.0/49.2  %, P  =  0.037). Minor allele frequen-
cies were 0.31 and 0.27 in controls and cases (microal-
buminuric  +  macroalbuminuric/ESRD), respectively 
(P  =  0.06). The strongest association was observed 
assuming recessive (CC vs. CG/GG, OR: 0.60, 95  % CI 
0.39–0.94; P = 0.031) and additive (CC vs. GG, OR: 0.60, 
95  % CI 0.38–0.95; P =  0.036) models. This association 
persisted after controlling for T2DM duration, gender, 
systolic BP, and triglycerides (OR: 0.52, 95  % CI 0.39–
0.90; P = 0.021). In contrast with the study by Pezolessi 
et al. [17], the rs451041 polymorphism in the CARS gene 
was not associated with DKD in this sample of T2DM 
patients. Moreover, none of the other analyzed SNPs was 
associated with this disease (Table 1).
Table  2 shows the genotype distribution of rs1888747 
SNP according to renal status (normo-, micro- or macro/
ESRD). The same pattern described above was observed, 
with a decrease in the frequency of the homozygous 
genotype (CC) for the minor allele of the rs1888747 SNP 
in subjects with microalbuminuria or macroalbuminu-
ria/ESRD compared to controls. The frequency of the C 
allele was also lower in individuals with microalbuminu-
ria or macroalbuminuria/ESRD compared to normoal-
buminuric controls. In addition, genotype distribution 
was compared between normo- and macro/ESRD groups 
(Table 2), and the same pattern was observed.
FRMD3 expression study: sample description
Since only rs1888747 was associated with DKD in this 
sample of subjects with T2DM, and this SNP is located 
near FRMD3 gene promoter region, we evaluated 
FRMD3 gene and protein expression in human kidney 
tissue. The mean age of the 91 subjects for the rs1888747 
SNP was 57.7 ± 14.2 years; 47.8 % were males, 55.4 % had 
arterial hypertension, 23.9  % were smokers, and 19.6  % 
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had diabetes. Additional file  1: Table S4 presents the 
clinical data according to rs1888747 genotypes. Geno-
type frequencies were as follows: GG, 51.1  % (n =  47), 
GC, 31.5 % (n = 29), and CC, 16.3 % (n = 15). The minor 
allele (C) frequency was 32 % in this sub-sample.
FRMD3 mRNA expression
FRMD3 mRNA expression in kidney tissue samples cat-
egorized according to the minor allele recessive model 
(CC vs. GG  +  GC) for the rs1888747 polymorphism 
are depicted in Fig.  1. Gene expression was similar in 
Table 1 Genotype distributions in T2DM patients with (cases) or without DKD (controls)
Data are presented as % (n)
T2DM type 2 diabetes mellitus, DKD diabetic kidney disease
Polymorphism Controls (n = 380) Cases (n = 718) P Dominant: OR (95 % CI)/P Recessive: OR (95 % CI)/P Additive: OR (95 % CI)/P
rs1888747
 CC 10.8 (41) 6.8 (49) 0.037 0.91 (0.71–1.16)/0.476 0.60 (0.39–0.94)/0.031 0.60 (0.38–0.95)/0.036
 CG 40.0 (152) 41.5 (298)
 GG 49.2 (187) 51.7 (371)
rs9521445
 AA 18.9 (72) 22.3 (160) 0.146 0.94 (0.71–1.23)/0.688 1.23 (0.90–1.67)/0.226 1.12 (0.78–1.61)/0.598
 AC 53.2 (202) 48.5 (348)
 CC 27.9 (106) 29.2 (210)
rs39075
 AA 17.9 (68) 19.4 (139) 0.139 0.85 (0.66–1.11)/0.264 1.10 (0.80–1.52)/0.611 0.97 (0.68–1.40)/0.963
 AG 49.5 (188) 44.4 (319)
 GG 32.6 (124) 36.2 (260)
rs451041
 AA 23.4 (89) 21.3 (153) 0.318 0.86 (0.65–1.13)/0.305 0.89 (0.66–1.19)/0.467 0.82 (0.58–1.16)/0.296
 AG 48.2 (183) 47.1 (338)
 GG 28.4 (108) 31.6 (227)
rs1041466
 GG 14.2 (54) 17.3 (124) 0.059 0.87 (0.67–1.13)/0.314 1.26 (0.89–1.78)/0.221 1.11 (0.76–1.63)/0.659
 AG 51.1 (194) 44.7 (321)
 AA 34.7 (132) 38.0 (273)
rs1411766
 AA 10.0 (38) 12.6 (91) 0.399 1.25 (0.97–1.60)/0.095 1.31 (0.88–1.95)/0.226 1.41 (0.93–2.13)/0.131
 AG 34.0 (129) 36.8 (264)
 GG 56.0 (213) 50.6 (363)
rs6492208
 CC 20.7 (79) 19.9 (143) 0.461 1.01 (0.78–1.31)/1.000 0.95 (0.70–1.29)/0.792 0.96 (0.68–1.36)/0.898
 CT 43.9 (167) 45.0 (323)
 TT 35.4 (134) 35.1 (252)
Table 2 Genotype distribution of rs1888747 polymorphism according to renal status
Data expressed as number of cases (%)
* P for comparisons among the three groups (normo- vs. micro- vs. macroalbuminuric/ESRD)
** P for comparison between normo- and macro/ESRD groups
Renal status
Genotype Normoalbuminuria (N = 380) Microalbuminuria (N = 323) Macro/ESRD (N = 395) P* P**
CC 41 (10.8) 25 (7.7) 24 (6.3) 0.04 0.05
GC 152 (40.0) 138 (42.7) 160 (40.9)
GG 187 (49.2) 160 (49.5) 211 (52.8)
C allele 0.31 0.29 0.26 0.02 0.03
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subjects homozygous for the C allele and in those carry-
ing the G allele [0.41 (−1.77 to 2.00) vs. 0.21 (−2.70 to 
2.05), respectively; P  =  0.630]. FRMD3 mRNA expres-
sion did not correlate with age (r2 = 0.11; P = 0.305), and 
did not differ between females and males [0.31 (−1.92 
to 2.05) vs. 0.12 (−2.70 to 2.00); P  =  0.200], between 
patients with or without hypertension [0.47 (−2.05 to 
2.05) vs. −0.21 (−2.70 to 1.99); P = 0.077] and between 
patients with or without diabetes [0.37 (−2.70 to 1.98) vs. 
0.16 (−2.22 to 2.05); P = 0.779].
It is worth noting that when separating diabetic from 
non-diabetic subjects, FRMD3 mRNA expression was 
also similar between genotype groups: CC (n  =  4) vs. 
GG + CG (n = 25) [0.34 (−2.70 to 1.98) vs. 0.54 (0.13–
1.17); P = 0.306] for the diabetic group, and CC (n = 9) 
vs. GG +  CG (n  =  48) [0.18 (−2.22 to 2.05) vs. −0.43 
(−1.77 to 2.00); P = 0.900] for the non-diabetic group.
FRMD3 protein expression
FRMD3 protein expression in kidney tissue samples 
categorized according to the recessive model (CC vs. 
GG + GC) of the rs1888747 polymorphism is shown in 
Fig.  2. FRMD3 total protein expression was similar in 
subjects homozygous for the C allele and in those car-
rying the G allele [1.17 (0.07–2.27) vs. 0.74 (0.11–2.87), 
respectively; P  =  0.190). Moreover, FRMD3 rs1888747 
genotypes did not influence FRMD3 protein levels after 
adjustment for age, sex and presence of DM (β = −0.019, 
P  =  0.908). However, FRMD3 protein concentra-
tions negatively correlate with FRMD3 gene expression 
(r2  =  −0.375; P  =  0.013). It is worth mentioning that 
when FRMD3 isoforms were quantified separately (data 
not shown), the data were similar to the quantification of 
the grouped isoforms.
Figure  2 depicts representative WB gels for FRMD3 
protein. Representative IHC photomicrographs of 
human kidney are represented in Fig. 3. FRMD3 protein 
was predominantly observed in tubules and podocytes. 
FRMD3 protein expression did not correlate with age 
(r2 = −0.13; P =  0.364) and was similar in females and 
males [0.73 (0.11–2.87) vs. 0.79 (0.07–2.64); P =  0.959] 
and in patients with or without arterial hypertension 
[0.73 (0.07–2.31) vs. 1.05 (0.11–2.87); P = 0.212]. FRMD3 
protein expression reached borderline formal statistical 
significance when comparing patients with or without 
diabetes [0.66 (0.11–2.31) vs. 0.99 (0.07–2.87); P = 0.05].
When separating diabetic from non-diabetic subjects, 
FRMD3 protein levels appeared to be similar between 
groups: CC (n = 2) vs. GG + CG (n = 20) [1.27 (0.27–
2.27) vs. 0.66 (0.16–2.31); P  =  0.193] for the diabetic 
group, and CC (n = 5) vs. GG + CG (n = 18) [1.17 (0.07–
1.85) vs. 0.90 (0.12–2.87); P = 0.969] for the non-diabetic 
group. Nevertheless, this result should be cautiously 
interpreted due to limited statistical power.
Discussion
In the present study, we found that rs1888747 SNP is 
associated with DKD in T2DM, as previously described 
for T1DM patients [15]. The CC genotype conferred pro-
tection against the development of DKD. Additionally to 
previous data from T1DM [15], a subgroup with microal-
buminuria was evaluated. The confirmation of this SNP 
with DKD in our population should be considered care-
fully, since frequently genetic association studies failed to 
be replicate in additional populations [13, 28, 29]. DKD 
is probably a multifactorial disorder resulting from an 
interaction between environmental and genetic factors. 
GWAS are capable of identifying unknown chromosomal 
regions that may be involved in the pathogenesis of DKD. 
However, replication of the findings in distinct popula-
tions is essential to confirm the associations observed in 
such studies.
The rs1888747 SNP (C/G) is an intergenic polymor-
phism, located near the promoter region of the FRMD3 
gene [30]. This gene encodes a structural/cytoskeletal 
protein involved in maintaining cellular shape [31, 32], 
but whose function remains otherwise unknown. Stud-
ies focusing on the relation between rs1888747 and DKD 
have been performed in T1DM and T2DM individuals 
of various ethnic backgrounds, such as Caucasians, Japa-
nese, African Americans, and Chinese, with conflicting 
results [15, 33–37].
A second SNP found in the GoKinD sample collection 
and replicated in DCCT/EDIC subjects is the rs451041 
SNP, located in chromosome 11p. The nearest gene to 
Fig. 1 FRMD3 gene expression in kidney samples according to the 
FRMD3 rs1888747 polymorphism (recessive model). P value was 
computed using Student’s t test. Results are expressed as n-fold 
differences from the calibrator sample and are presented as medians 
(minimum–maximum values)
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Fig. 2 FRMD3 protein expression according to the FRMD3 rs1888747 polymorphism (recessive model). a FRMD3 protein expression according to 
the FRMD3 rs1888747 polymorphism (recessive model). P value was computed using Student’s t test. Results are expressed as n-fold changes and 
are presented as medians (minimum–maximum values). Representative western blots for: b β-actin, and c three isoforms of FRMD3
Fig. 3 Representative photomicrographs of human kidney by immunohistochemistry for FRMD3 protein. a, b FRMD3 protein expression is 
predominantly localized in tubules. In glomerus, the expression is localized exclusively in podocytes. Arrows indicate different areas of FRMD3 
immunostaining. c, d Negative control samples. Original magnification of all images ×400
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rs451041 is CARS, which is expressed in mesangial and 
proximal tubule cells. Mutations in this gene have been 
associated with neurodegenerative diseases and cysti-
nosis [38, 39]. However, neither this nor the other SNPs 
originally associated with DKD in T1DM patients were 
associated with DKD in the present study with patients 
with T2DM. Although this finding requires further vali-
dation, if confirmed it might suggest that different genes 
are involved in the development of DKD in T1DM and 
T2DM.
The evidence to infer susceptibility genes contributing 
to the pathogenesis of DKD remains elusive. Advances 
in genotyping technologies have allowed the identifica-
tion of several chromosomal regions potentially associ-
ated with DKD. Nevertheless, methodological limitations 
such as lack of statistical power, differences regarding the 
population studied and phenotypes analyzed make it dif-
ficult to compare some of the study findings and build up 
on results.
In the present study, we also aimed to evaluate if the 
rs1888747 risk allele was influencing FRMD3 gene and/
or protein expression. Unfortunately, we were not able 
to demonstrate an association of these variables with 
the different genotypes. The FRMD3 gene (ID: 257019) 
is located on chromosome 9q21.32, size of 2.282 pb; 21 
exons; 81.4  Mb position (http://www.ncbi.nlm.nih.gov/
gene/257019). Members of the protein 4.1 family have 
well characterized functions in a variety of cell types, 
including rat nephron [31, 32]. FRMD3 is present in adult 
ovaries as well as fetal skeletal muscle, brain, and thymus 
[40]. Our findings confirm that FRMD3 is expressed in 
proximal renal tubular cells and human podocytes, as 
previously shown [14, 35], suggesting that this protein is 
involved in maintaining the function and integrity of the 
slit diaphragm. Therefore, it is a good candidate gene for 
albuminuria development. Furthermore, FRMD3 protein 
concentrations negatively correlated with FRMD3 gene 
expression. Although this needs further confirmation, it 
suggests that FRMD3 mRNA levels may not reflect the 
expression of the protein itself, probably due to impor-
tant translational regulation mechanisms.
Recently, changes in FRMD3 expression have been 
linked to progression of DKD in a group of 22 Pima Indi-
ans with T2DM [41]. The authors proposed an influence 
of the rs1888747 polymorphism in the FRMD3 promoter 
on transcriptional regulation within the bone morpho-
genetic protein (BMP)-signaling pathway [41], suggest-
ing that the transcriptional coregulation of BMP pathway 
members and FRMD3 might be mediated by the four 
transcription factor binding site (TFBS) promoter mod-
ules in the functional context of DKD [42]. The mecha-
nism mediating the connection between FRMD3 and 
BMP pathway members remains unknown. No evidence 
at the protein, RNA, or microRNA levels was found [42]. 
The present findings, derived from genotyping, gene 
and protein expression studies in human kidney tis-
sue, are important to elucidate the role of the rs1888747 
polymorphism. Even so, further research is necessary to 
confirm our observations and to unveil the mechanisms 
underlying the association of the rs1888747 polymor-
phism with DKD.
A limitation of case–control studies of DKD such 
as the present one is survival bias. However, we do not 
believe that this had an impact on the results we report, 
because minor allele frequency was similar in mild and 
severe stages of DKD, although data from the prospec-
tive DCCT/EDIC cohort [16] suggest that the rs1888747 
G allele had a faster progression to severe DKD. Another 
possible limitation of our study is the fact that the sam-
ples for the expression studies were not obtained from 
patients with DKD, but instead from patients undergo-
ing therapeutic nephrectomy. Thus, the present gene 
and protein expression findings cannot be directly trans-
lated to patients with DKD. Further studies are necessary 
to determine if the rs1888747 SNP is or not related to 
changes in FRMD3 gene and protein expression in DKD.
In conclusion, the present study replicates the protec-
tive effect of rs1888747 SNP against established DKD 
previously described for T1DM and T2DM. Moreo-
ver, in agreement with previous data, it also shows that 
this effect is already present in less advanced stages of 
DKD, such as microalbuminuria. Outside the context 
of diabetes, this study was not able to show an influ-
ence of rs1888747 SNP on FRMD3 gene and/or protein 
expression.
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